Inovio rumored to have rejected GlaxoSmithKline takeover offer, Daily Mail says Speculation within the medical sector is "rife" with rumors that Inovio (INO) has rejected an $18 per share cash offer from GlaxoSmithKline (GSK), reports the Daily Mail, without citing sources. Roche (RHHBY), Merck (MRK), and Bristol Myers (BMY) are all "believed to be interested" in the company, said the report. Inovio is up just over 3.8% in after-hours trading after rising 5% before the close, and currently sits at $9.36. The company is trialing several "immunotherapy" treatments, a type of treatment which, according to the Daily Mail, could replace chemotherapy as the standard of care for cancer patients.